0
0
NEW DELHI – As the countdown to the Union Budget 2026-27 begins, India’s healthcare landscape stands at a critical crossroads. With Finance Minister Nirmala Sitharaman set to present the budget on February 1, a powerful coalition of medical professionals, patient advocacy groups, and industry leaders is calling for a paradigm shift in how the nation finances the health of its 1.4 billion citizens.
The central demands are clear: a significant hike in public health spending to finally meet long-standing targets, and the immediate removal of tax burdens—specifically Goods and Services Tax (GST)—on lifesaving medical equipment and vaccines. As non-communicable diseases (NCDs) like cancer and chronic genetic conditions like thalassemia place an increasing strain on the Indian economy, experts argue that fiscal policy must now be treated as a tool for public health.
The Gap Between Policy and Reality
For years, the National Health Policy has aimed for public health expenditure to reach 2.5% of the Gross Domestic Product (GDP). However, current spending continues to hover significantly below this benchmark, lagging behind other developing economies with similar growth trajectories.
“India must raise public health spending to 2.5-5% of GDP,” says Jyotsna Govil, Chairperson of the Indian Cancer Society (Delhi Branch). She emphasizes that the current “unequal access” to care is a direct result of underfunding in infrastructure and prevention.
This sentiment is echoed by Dr. Vinay Aggarwal, former National President of the Indian Medical Association (IMA). Dr. Aggarwal advocates for a tax-funded universal healthcare model. “Increasing the allocation is about more than just buildings; it’s about strengthening government hospitals and human resources,” he explains.
Easing the Burden: The Case for GST Relief
One of the most pressing issues facing patients today is the “tax on survival.” Currently, essential medical items carry various tax rates that significantly inflate the cost of long-term care.
The Thalassemia Crisis
For patients with thalassemia—a genetic blood disorder requiring lifelong blood transfusions and medication—the financial toll is staggering. Deepak Chopra of the Thalassemia Patients Advocacy Group (TPAG) highlights a startling breakdown of costs:
-
Infusion Pumps: 32% Customs Duty + 12% GST.
-
Chelation Medicines: 5% GST.
-
Bedside Filters: 5% GST.
“Since these medicines and equipment are life-saving and indispensable, we strongly request that customs duty and GST be completely removed,” Chopra told IANS. For a family managing a chronic condition, these percentages represent the difference between consistent treatment and dangerous lapses in care.
The Cancer Challenge
The oncology sector is also seeking relief. Beyond equipment, experts are pushing for the universal HPV vaccination to be integrated into the public health fold to prevent cervical cancer, alongside GST exemptions for all vaccines and consumables.
Strengthening the “Make in India” Ecosystem
While patient advocates focus on immediate affordability, industry bodies are looking at long-term sustainability through domestic manufacturing.
Rajiv Nath, Forum Coordinator for the Association of Indian Medical Devices (AiMeD), has urged the government to increase import tariffs on medical devices from the current 7.5% to 10-15%. The goal is to discourage reliance on expensive imports and incentivize suppliers who achieve over 50% local value addition.
Meanwhile, Pavan Choudary, Chairman of the Medical Technology Association of India (MTaI), suggests that insurance coverage must expand to include more advanced, effective procedures. This, he argues, would not only improve patient outcomes but also encourage “responsible medical innovation” within the country.
Reforming Ayushman Bharat (PMJAY)
The Pradhan Mantri Jan Arogya Yojana (PMJAY), India’s flagship health insurance scheme, is a cornerstone of the current system, but experts say it requires a “Version 2.0” upgrade.
Dr. Aggarwal and other leaders are calling for:
-
Inclusion of Outpatient Care: Currently, the scheme largely covers hospitalization, leaving the cost of consultations and diagnostics to the patient.
-
Realistic Package Rates: Ensuring that the government’s reimbursement to hospitals actually covers the cost of modern medical care.
-
Support for Small Hospitals: Providing infrastructure financing and credit guarantees to small and medium-sized private hospitals that serve rural and semi-urban populations.
Public Health Implications: Why It Matters to You
For the average citizen, the outcome of the February 1 budget will be felt at the pharmacy counter and the hospital billing desk.
-
Preventive Care: A boost in spending could mean more district-level screening centers for cancer, allowing for early detection when treatment is most effective and least expensive.
-
Digital Health: Increased funding for “technology-enabled care” could expand tele-medicine services, bringing specialist advice to remote villages.
-
Lower Costs: If the government heeds the call for GST removal, the retail price of life-saving drugs and vaccines should theoretically drop, reducing out-of-pocket expenditure—which currently accounts for nearly 50% of total health spending in India.
Limitations and Counterarguments
While the call for increased spending is nearly universal among health experts, economists often point to the “fiscal tightrope.” Drastic increases in health spending require either higher taxation in other sectors or a widening of the fiscal deficit. Furthermore, simply throwing money at the problem is not enough; critics argue that without deep-rooted administrative reforms to tackle corruption and inefficiency in public hospitals, increased budgets may not reach the patients who need them most.
Additionally, while raising import tariffs supports “Make in India,” some healthcare providers worry it could lead to short-term price hikes for specialized equipment that cannot yet be manufactured locally to the same standards as global imports.
The Road Ahead
As the Finance Ministry puts the final touches on the 2026-27 Budget, the healthcare sector’s message is unified: Health is an investment, not an expense. By aligning fiscal policy with clinical needs—through GST relief, infrastructure spending, and support for domestic innovation—India has the opportunity to build a “cancer-resilient” and “health-secure” nation.
Would you like me to provide a breakdown of how current GST rates compare to the proposed “zero-tax” model for specific medical conditions?
References
- https://tennews.in/budget-2026-experts-urge-public-spending-boost-gst-relief-on-lifesaving-equipment-vaccines/
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
